CINECA IRIS Institutional Research Information System

VITALE, Candida
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.824
EU - Europa 3.096
AS - Asia 1.533
AF - Africa 83
SA - Sud America 25
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 22
Totale 9.606
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.777
CN - Cina 927
IT - Italia 713
IE - Irlanda 494
SE - Svezia 393
DE - Germania 315
UA - Ucraina 266
AT - Austria 208
SG - Singapore 204
FR - Francia 188
FI - Finlandia 121
IN - India 90
VN - Vietnam 89
KR - Corea 77
GB - Regno Unito 71
PL - Polonia 67
SN - Senegal 54
DK - Danimarca 53
CA - Canada 41
HK - Hong Kong 41
NL - Olanda 36
BY - Bielorussia 34
GR - Grecia 28
JP - Giappone 28
RU - Federazione Russa 26
EU - Europa 21
BE - Belgio 20
CH - Svizzera 19
ES - Italia 18
AU - Australia 17
BR - Brasile 17
TW - Taiwan 12
UZ - Uzbekistan 12
IR - Iran 9
RO - Romania 9
TR - Turchia 7
IL - Israele 6
NZ - Nuova Zelanda 6
ZA - Sudafrica 6
EG - Egitto 5
ID - Indonesia 5
MX - Messico 5
TH - Thailandia 5
MA - Marocco 4
NG - Nigeria 4
PT - Portogallo 4
SA - Arabia Saudita 4
AM - Armenia 3
IQ - Iraq 3
MY - Malesia 3
PK - Pakistan 3
RS - Serbia 3
AR - Argentina 2
BD - Bangladesh 2
CI - Costa d'Avorio 2
CO - Colombia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
LU - Lussemburgo 2
MU - Mauritius 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
BW - Botswana 1
EC - Ecuador 1
HU - Ungheria 1
IM - Isola di Man 1
MK - Macedonia 1
MM - Myanmar 1
PA - Panama 1
TN - Tunisia 1
UY - Uruguay 1
Totale 9.606
Salva come PNG Salva come JPEG
Città #
Chandler 850
Beijing 583
Dublin 493
Ann Arbor 269
Ashburn 251
Fairfield 221
Houston 212
Vienna 207
Jacksonville 199
Medford 180
Nyköping 171
Torino 171
Wilmington 168
Dearborn 167
Princeton 144
Woodbridge 116
San Mateo 101
Singapore 99
Seattle 91
Villeurbanne 80
Redwood City 72
Cambridge 69
Fremont 61
Dong Ket 58
Warsaw 52
New York 44
Florence 33
Nanjing 32
Turin 32
Washington 32
Chengdu 29
Hangzhou 29
Hefei 29
Pisa 28
Rome 28
Milan 23
Boston 22
Los Angeles 22
Norwalk 22
Toronto 22
San Diego 21
Shanghai 21
Chennai 20
Seoul 20
Brussels 18
Guangzhou 18
Central District 17
Boardman 16
Düsseldorf 16
San Jose 15
Hong Kong 14
Nürnberg 13
Wuhan 13
Kunming 12
Bologna 11
Hebei 11
Munich 11
Taipei 11
Upper Marlboro 11
Zhengzhou 11
Helsinki 10
São Paulo 10
Duncan 9
Falls Church 9
Linden 9
Nanchang 9
Rotterdam 9
Guiyang 8
Hyderabad 8
Oerlikon 8
Ottawa 8
Paris 8
Piemonte 8
Provo 8
Pune 8
Shenyang 8
Xian 8
Changsha 7
Codogno 7
Mountain View 7
Philadelphia 7
Phoenix 7
Tokyo 7
Chicago 6
Dallas 6
Jinan 6
Liverpool 6
Monza 6
Mortara 6
Palermo 6
Valdagno 6
Wayne 6
Bucharest 5
Casorzo 5
Columbus 5
Erlangen 5
Jaipur 5
London 5
Silver Spring 5
Tauranga 5
Totale 6.093
Salva come PNG Salva come JPEG
Nome #
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 279
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 276
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 271
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 191
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 189
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 179
Richter Syndrome in Chronic Lymphocytic Leukemia 165
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 154
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 135
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 133
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 129
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 128
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 120
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 120
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences 119
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 113
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 104
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 104
The tryptophan metabolism in the immune dysregulation of multiple myeloma 102
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 101
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 99
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 98
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib 98
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 97
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 94
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 94
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 93
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 93
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life 92
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 91
t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia 91
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 90
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 89
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 89
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 88
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 88
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 87
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 87
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 85
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 84
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 84
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 82
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 81
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 80
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 80
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 80
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 79
Real life use of bendamustine in elderly patients with lymphoid neoplasia 79
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 78
Chronic lymphocytic leukemia therapy: new targeted therapies on the way 78
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial 76
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 74
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 74
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study 72
Mutual interactions between tumor cells, the immune system and the microenvironment in chronic lymphocytic leukemia: biological insights and potential therapeutic implications 72
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide 72
The CXCR4 downstream signaling pathways in chronic lymphocytic leukemia: a target to reverse microenvironment protection 71
LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 71
Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: Correlation between responses and immune characteristics 71
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT 70
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 70
The Hypoxia-Inducible Factor-1 alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance 69
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 69
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial 68
Role of ward pharmacist in management of systemic antifungal drugs in hematology department of San Giovanni Battista Hospital, Turin, Italy. 68
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. 68
The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells 67
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells 66
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs 65
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target 64
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells 64
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia 63
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 63
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 62
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 61
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 60
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll 60
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells 59
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 59
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE 59
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia 58
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape 58
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib 58
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 58
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL 57
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA 57
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia 56
The role of clinical team pharmacist of San Giovanni Battista Hospital in a retrospective study invasive fungine infections: management and appropiateness. 54
Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia 54
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 54
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia 50
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia 50
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia 49
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 47
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia 47
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside 45
Changes in lymphocyte subsets, angiogenic factors and plasma cytokines in patients with chronic lymphocytic leukemia during treatment with Ofatumumab and Lenalidomide 45
CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results 45
Monoclonal antibodies as selective diagnostic and therapeutical tools in benign and neoplastic prostatic pathologies 44
Totale 8.829
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.574
article - articoli 0
book - libri 0
conference - conferenze 17.052
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.626
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.301 0 39 47 178 80 185 154 111 109 143 132 123
2020/20211.721 146 122 75 150 235 95 99 132 137 81 226 223
2021/20221.863 81 44 84 163 108 42 237 133 49 197 417 308
2022/20232.278 247 219 66 235 185 571 171 147 227 62 94 54
2023/2024968 114 183 61 43 50 171 23 71 7 55 64 126
2024/202520 16 4 0 0 0 0 0 0 0 0 0 0
Totale 9.984